Signature Biologics News, Researches, Clinical Trials and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Powered by Hostinger

Latest Articles

FDA Allows Expanded Enrollment in Signature Biologics’ DMD Cell Therapy Study

Press Releases August 11, 2026 0

Signature Biologics has announced that the U.S. Food and...

Exon 45 Skipping in DMD: Deletions and Mutations That May Be Eligible

DMD August 10, 2026 0

As of recent years, exon skipping has emerged as...

Mutations and Deletions Amenable to Exon 44 Skipping Therapies for Duchenne Muscular Dystrophy

DMD August 9, 2026 0

Deletions amenable to exon 44 skipping are specific genetic...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Therapies December 26, 2024 0

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 0

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 0

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

Signature Biologics

Must Read

Elevidys Under Scrutiny: A Candid Interview with the Turkish Representative of DMDWarrioR on Cost, Effectiveness, and Ethics

Psychological Support in DMD: Coping Strategies for Families and Children After Diagnosis

Vamorolone (Agamree) Rejected by INESSS: When Cost Takes Priority Over Compassion in DMD Care